SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 695.46+2.0%Nov 13 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Felix B who wrote (2768)10/23/2019 12:08:12 AM
From: Miljenko Zuanic   of 3557
 
Point is that there is no *magic* about keytruda be *extremely* better than other anti-PD1. So, IF company execute trials well chance to have good results and be able to compete (with data and maybe with discount) are not small. Add some proprietary combinations (cancer field is SO REACH) and you have nice return on investment. REGN need positive outcome on cancer-abs development front, they need to re-gain investor confidence.
Some data will (may) be available by mid-2020 to year-end.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News